Breaking News
Researchers at Ben-Gurion University of the Negev in Israel have discovered a way to destroy harmful “senescent” cells that accumulate with age and increase the kind of tissue damage and inflammation that slowly causes life to end.
The U.S. Food and Drug Administration has approved KEYTRUDA and KEYTRUDA QLEX in combination with Padcev, as neoadjuvant treatment and then continued after cystectomy as adjuvant treatment, for the treatment of adult patients with muscle-invasive bladder cancer who are ineligible for cisplatin-based chemotherapy.
Researchers re-engineered the structure of the commonly ussed chemotherapy drug 5-fluorouracil (5FU) into that of a “spherical nucleic acid” — a nanostructure that weaves the drug directly into DNA strands coating tiny spheres, making its cancer cell-killing ability 20,000 more effective, while also reducing its toxicity.
BioTrending
- By Keith Berman, MPH, MBA
Therapeutic plasma exchange may improve outcomes for patients diagnosed with sepsis or septic shock, but funding is needed to conduct needed clinical trials.
- By Trudie Mitschang
As chronic disease and aging populations drive healthcare costs higher, value-based care offers a sustainable path forward — rewarding providers for better outcomes, improved patient experiences and greater cost-efficiency.
- By Diane L.M. Cook
With a pending shortage of cardiologists, there is a growing need for remote cardiac monitoring, and now, three FDA-cleared products are transforming how this care is provided.
- By Lee Warren
The use of AI is growing at a brisk rate as healthcare professionals realize its potential as an indispensable partner in treating patients.
Awards
BSTQ is an Industry Award-Winning Journal
Since its debut in 2009, BioSupply Trends Quarterly’s articles have been recognized by some of the industry’s most prominent organizations, earning platinum and gold awards.
